Previous Article | Next Article 
Infection and Immunity, June 1999, p. 2810-2814, Vol. 67, No. 6
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Platelet-Activating Factor Induces Nitric Oxide
Synthesis in Trypanosoma cruzi-Infected Macrophages and
Mediates Resistance to Parasite Infection in Mice
Júlio C. S.
Aliberti,1
Fabiana S.
Machado,1
Ricardo T.
Gazzinelli,2
Mauro M.
Teixeira,3 and
João S.
Silva1,*
Department of Immunology, School of Medicine
of Ribeirão Preto, University of São Paulo, Ribeirão
Preto, São Paulo,1 and Department
of Biochemistry and Immunology2 and
Department of Pharmacology,3 ICB,
UFMG, Belo Horizonte, Minas Gerais, Brazil
Received 22 January 1999/Accepted 4 March 1999
 |
ABSTRACT |
Trypanosoma cruzi replicates in nucleated cells and is
susceptible to being killed by gamma interferon-activated macrophages through a mechanism dependent upon NO biosynthesis. In the present study, the role of platelet-activating factor (PAF) in the induction of
NO synthesis and in the activation of the trypanocidal activity of
macrophages was investigated. In vitro, PAF induced NO secretion by
T. cruzi-infected macrophages and the secreted NO inhibited intracellular parasite growth. The addition of a PAF antagonist, WEB
2170, inhibited both NO biosynthesis and trypanocidal activity. The
inducible NO synthase/L-arginine pathway mediated
trypanocidal activity, since it was inhibited by treatment with
L-N-monomethyl arginine (L-NMMA),
an L-arginine analog. PAF-mediated NO production in
infected macrophages appears to be dependent on tumor necrosis alpha
(TNF-
) production, since the addition of a neutralizing anti-TNF-
monoclonal antibody mAb inhibited NO synthesis. To test the role of PAF
in mediating resistance or susceptibility to T. cruzi
infection, infected mice were treated with WEB 2170, a PAF antagonist.
These animals had higher parasitemia and earlier mortality than did
vehicle-treated mice. Taken together, our results suggest that PAF
belongs to a group of mediators that coordinate the mechanisms of
resistance to infections with intracellular parasites.
 |
INTRODUCTION |
Infection with the protozoan
flagellate Trypanosoma cruzi causes Chagas' disease, a
major public health problem in many Latin American countries. Infection
of mice with T. cruzi is a widely used model in the study of
the pathophysiological mechanisms underlying the disease and host
protection. There is evidence to suggest a central role for
macrophage-derived nitric oxide (NO) in mediating resistance to
T. cruzi infection (12, 23, 29). In macrophages, NO is generated from the guanidino nitrogen atom of
L-arginine by an inducible NADPH-dependent enzyme, NO
synthase (NOS) (19-21). The inducible isoform of NOS, iNOS,
is induced in macrophages by cytokines such as gamma interferon
(IFN-
) and tumor necrosis factor alpha (TNF-
) (9, 10).
The lipid mediator platelet-activating factor
(1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphorocholine)
(PAF) is produced by a variety of inflammatory cells, including
macrophages, neutrophils, basophils, eosinophils, platelets, and
endothelial cells (3, 4, 7, 18). PAF has been implicated in
a number of pathological conditions, including endotoxic shock,
thrombosis, allergic reactions, and a variety of other inflammatory
diseases (3, 8, 14, 15). More recently, a few studies have
demonstrated that PAF is also capable of activating monocytic cells to
express iNOS and produce NO (28). The PAF-induced NO
production in macrophages appears to have tumoricidal activity in vitro
(13). Interestingly, the endogenous release of PAF appears
to play an important role in the production of NO following the
activation of murine macrophages with LPS (28).
In the present study, we have investigated whether PAF plays a role in
mediating resistance against T. cruzi infection both in
vitro and in vivo. Our results show that PAF-activated macrophages release NO that leads to trypanocidal activity and suggest a role for
endogenous PAF in mediating protection against T. cruzi
infection in mice.
 |
MATERIALS AND METHODS |
Experimental animals.
Female BALB/c or C3H/HeJ mice, 6 to 8 weeks old, were bred and maintained under standard conditions in the
animal house of the Department of Immunology, University of São
Paulo, Ribeirão Preto, São Paulo, Brazil.
Parasites and experimental infections.
The Y strain of
T. cruzi was used in all experiments. For experiments in
vitro, trypomastigote forms were grown in and purified from the monkey
kidney fibroblast cell line LLC-MK2. BALB/c mice were
infected intraperitoneally with 104 blood-derived
trypomastigote forms. Parasitemia levels in 5 µl of blood obtained
from the tail vein were measured as previously described
(17).
In vivo treatment with WEB 2170.
Infected mice received an
intraperitoneal injection of the PAF antagonist WEB 2170 (10 mg/kg;
Boehringer, Ingelheim, Germany) or vehicle (phosphate-buffered saline;
10 ml/kg) 20 min prior to infection and then daily for the first 15 days postinfection as previously reported (22). Parasitemia
levels and mortality rates were evaluated throughout the acute phase of infection.
Macrophage cultures.
C3H/HeJ and BALB/c mouse inflammatory
macrophages were harvested from peritoneal cavities 3 days after the
injection of 1 ml of 3% sodium thioglycolate (Difco Laboratories,
Detroit, Mich.). The adherent cells were obtained after a 2- to 4-h
incubation of single-cell suspensions in 24-well tissue culture plates
at 37°C. The nonadherent cells were removed by exhaustive washing with Hanks' medium. Parasites were added in a 1:1 parasite:cell ratio
with or without anti-TNF-
monoclonal antibody (MAb) (XT 22.11; 50 µg/ml) and incubated for 6 h at 37°C in a humidified chamber
containing 5% CO2. Culture supernatants were harvested 48 h later and stored at
20°C for later nitrite determination.
Microbicidal activity.
Peritoneal macrophages were harvested
from mice 3 days after injection of 1 ml of 3% (wt/vol) sodium
thioglycolate (Sigma). The cells (106/ml) were plated onto
chamber slides (Nunc) and incubated overnight. Adherent cells were
infected at a parasite-to-cell ratio of 1:1 for 120 min. Extracellular
parasites were removed by six washes with RPMI 1640, and the cells were
incubated at 37°C in 5% CO2 in the presence or absence
of various concentrations of PAF, lyso-PAF (Bachem Inc.), WEB 2170 (10
5 to 10
9 M), recombinant murine IFN-
(Life Technologies, Bethesda, Md.) (1 to 100 U/ml), or
L-N-monomethyl arginine (L-NMMA; 200 mM) (Sigma). The supernatants were harvested and assayed for nitrite
concentration. Growth of parasites in the macrophages was measured by
counting the trypomastigotes released 5 days after the infection and by counting the intracellular amastigote forms 4 and 48 h
postinfection, as previously described (25).
NO quantification.
The nitrite concentration in the culture
supernatants was assayed in a microplate by mixing 0.1 ml of culture
supernatant with 0.1 ml of Griess reagent (29). The
absorbance at 550 nm was read 10 min later, and the
NO2
concentration was determined by reference
to a standard curve of 1 to 100 µM NaNO2.
Statistics.
Statistical analysis of the differences between
mean values obtained for experimental groups was done by Student's
t test, and that for unpaired correlations was done by the
Spearmon test.
 |
RESULTS |
PAF induces the production of NO in T. cruzi-infected
macrophages.
The addition of increasing concentrations of PAF
(10
9 to 10
7 M) led to a significant
production of NO in C3H/HeJ-derived macrophages infected with T. cruzi (Fig. 1A). As seen in Fig.
2, PAF alone induced little NO production
but significantly synergized with T. cruzi infection to
enhance NO levels. The levels of NO detected in response to PAF were
markedly lower than those observed when infected macrophages were
stimulated with IFN-
(Fig. 1B). The effects of PAF were receptor
mediated as assessed by measuring the inhibitory effects of the PAF
receptor antagonist WEB 2170 on PAF-induced NO production (Fig.
3). In addition, the inactive metabolite
of PAF, lyso-PAF, was ineffective in enhancing NO production by
infected macrophages. PAF-induced NO production was abrogated by
treatment with the NOS inhibitor L-NMMA (Fig. 3). The
levels of NO production by macrophages in the presence of WEB 2170 were markedly lower than in the presence of parasite alone (Fig. 3). Similar
results were obtained when BALB/c mouse macrophages were infected.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
PAF induces NO production by T. cruzi-infected macrophages. C3H/HeJ-derived thioglycolate-elicited
peritoneal macrophages were cultured with T. cruzi
trypomastigotes (Y strain) at a parasite-to-host cell ratio of 1:1 for
48 h in the presence of PAF (A) or IFN- (B) at 37°C in a
humidified chamber containing 5% CO2. The supernatants
were harvested, and the nitrite concentration was assayed by the Griess
method. Bars represent the mean and standard deviation (SD) of
triplicate samples from one of three independent experiments. *,
P < 0.05 compared with the values obtained with
infected cells cultured in medium (Med) alone.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Anti-TNF- MAb inhibits PAF-induced NO production.
C3H/HeJ-derived peritoneal macrophages were cultured with T. cruzi trypomastigotes (Tc) at a parasite-to-cell ratio of 1:1 with
or without PAF (10 7 M) or PAF plus anti-TNF- MAb
(aTNF) (50 µg/ml). After 48 h, the supernatants were harvested
and the nitrite concentration was assayed by the Griess method. Bars
represent mean ± SD of triplicate samples. The results are
representative of three independent experiments. *, P < 0.05 compared with the values obtained with cells cultured in the
presence of medium (Med) alone.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
WEB 2170 and L-NMMA inhibit PAF-induced NO
production. C3H/HeJ-derived peritoneal macrophages were cultured with
T. cruzi trypomastigotes (Tc) at a parasite-to-cell ratio of
1:1 with or without PAF (10 7 M) plus WEB 2170 (WEB)
(10 5 M), PAF plus L-NMMA (LN) (200 mM), or
lyso-PAF (Lyso) (10 7 M). After 48 h, the
supernatants were harvested and the nitrite concentration was assayed.
Bars represent the mean and SD of triplicate samples. The results are
representative of three independent experiments. *, P < 0.05 compared with the values obtained with cells cultured in the
presence of medium alone.
|
|
Pretreatment of infected macrophages with a neutralizing MAb raised
against murine TNF-
effectively inhibited the production of NO in
response to PAF. Similarly, the anti-TNF-
MAb blocked the low levels
of NO produced by noninfected macrophages treated with PAF (Fig. 2).
PAF-induced NO production controls the growth of T. cruzi in macrophages.
To evaluate whether PAF could affect
parasite growth, infected macrophages were stimulated in vitro with PAF
and parasite growth was evaluated by counting intracellular parasites
soon after infection (4 h postinfection) or 48 h postinfection.
The addition of PAF to infected C3H/HeJ-derived macrophages resulted in
a concentration-dependent inhibition of parasite growth (Fig. 4A). For example, addition of
10
7 M PAF caused a greater than 90% reduction in
parasite count compared with the outcome of incubation with medium
alone. Inhibition of parasite replication by macrophages treated with
IFN-
is also shown for comparison (Fig. 4B).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Parasite growth is inhibited in PAF-treated macrophages.
C3H/HeJ-derived peritoneal adherent cells were cultured with T. cruzi trypomastigotes at a parasite-to-host-cell ratio of 1:1 and
with various concentrations of PAF (A) or IFN- (B) in a humidified
chamber containing 5% CO2 at 37°C. The number of
intracellular parasites in at least 500 cells was determined by light
microscopy. Symbols represent the mean and SD of triplicate counts of
100 cells. The data are representative of three independent
experiments. *, P < 0.05 compared to the values
obtained with infected cells cultured in medium alone.
|
|
The inhibitory effects of PAF on parasite growth were counteracted by
addition of a PAF antagonist, WEB 2170 (Fig.
5). Moreover,
the inactive metabolite of
PAF, lyso-PAF, did not induce trypanocidal
activity in C3H/HeJ-derived
macrophages (Fig.
5). A role for NO
production in the trypanocidal
activity of PAF was shown by using
L-NMMA. This NOS
inhibitor effectively reversed the ability of
PAF to induce infected
macrophages to kill
T. cruzi (Fig.
5).
The number of
parasites released by macrophages on day 5 after
infection was also
significantly inhibited (by more than 53%)
when exogenous PAF
(10
7 M) was added (Fig.
6).
Similar results were obtained when BALB/c-derived
macrophages were
used. For comparison, addition of 100 U of recombinant
IFN-

per ml
inhibited parasite growth (99%), and IFN-

was significantly
more
effective than PAF in the control of parasite replication.
Together,
our in vitro results demonstrate the ability of exogenous
PAF to induce
both NO production and trypanocidal activity in
infected macrophages.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
PAF-induced microbicidal activity is decreased by
inhibition of the PAF receptor or iNOS activation. C3H/HeJ-derived
peritoneal adherent cells were infected with T. cruzi
trypomastigotes at a parasite-to-host-cell ratio of 1:1 in the absence
of stimulus (Med) or with lyso-PAF (L-PAF) (10 7 M) or PAF
(10 7 M) with or without WEB 2170 (10 5 M)
(WEB) or L-NMMA (200 mM) (LN) and cultured for 48 h in
a humidified chamber containing 5% CO2 at 37°C. Bars
represent the mean and SD of triplicate counts of the number of
intracellular parasites found in 100 macrophages. The data are
representative of three independent experiments. *, P < 0.05 compared to the values obtained with infected cells cultured
in medium alone.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
The presence of PAF decreases the release of parasites
from infected macrophages. C3H/HeJ-derived peritoneal macrophages were
infected with T. cruzi trypomastigotes (Y strain) at a
parasite-to-host-cell ratio of 1:1 in a humidified chamber containing
5% CO2 at 37°C. Two hours later, extracellular parasites
were removed and the infected cells were incubated with medium alone
(Med), PAF (10 7 M), or IFN- (100 U/ml). On day 5 postinfection, the parasites released into the medium were counted.
Bars represent the mean and SD of triplicate samples and are
representative of three independent experiments. *, P < 0.05 compared to the values obtained with infected cells cultured
in medium alone.
|
|
The blockade of PAF receptors in an animal model of acute T. cruzi infection enhances parasitemia and animal death rates.
Next we examined a role for PAF in a T. cruzi infection
model in mice. BALB/c mice were treated daily with WEB 2170 or vehicle for 15 days during the acute phase of infection. Parasitemia and mortality were evaluated from days 5 to 15 postinfection. Treatment during the first 15 days postinfection resulted in a significant increase in parasitemia on days 7 and 8 compared with that in infected
mice receiving vehicle only. On day 8, the parasitemia in WEB
2170-treated mice was 21-fold higher than that in vehicle-treated animals (Fig. 7A). In addition, WEB
2170-treated mice had significantly lower survival rates than did
vehicle-treated mice (Fig. 7B). WEB 2170-treated animals had 100%
mortality around day 24 after infection, whereas vehicle-treated mice
had 60% mortality at that time.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
PAF mediates resistance in mice infected with T. cruzi. BALB/c mice were infected with 104 (A) or
103 (B) blood trypomastigotes and treated with WEB 2170 ( ) or with vehicle ( ) 4 h before and again once daily after
infection with T. cruzi. Parasitemia (A) and survival rates
(B) were evaluated during the acute phase. Lines represent means and SD
of data obtained with 10 mice per group in one of three independent
experiments. *, P < 0.05 compared to the values
obtained for parasitemia in vehicle-treated mice.
|
|
 |
DISCUSSION |
PAF is a membrane-derived phospholipid with widely
recognized proinflammatory activities. PAF is produced and exerts its
biological actions in a variety of cells, including neutrophils,
eosinophils, lymphocytes, and macrophages. Moreover, it has been
implicated in several systemic and organ-specific disorders, such as
allergic inflammation and endotoxic shock (3, 7, 16).
However, much less is known about its role during infection, and, to
our knowledge, there have been no studies evaluating the role of PAF during infections with the protozoan T. cruzi. It has been
shown that PAF induces the production of NO in monocytic cells
(28) and that NO derived from activated macrophages is
cytostatic or cytotoxic for a variety of pathogens (20, 21).
In the present study, we evaluated the role of PAF in modifying
T. cruzi infection both in vitro and in vivo.
Pretreatment of T. cruzi-infected macrophages from C3H/HeJ
or BALB/c mice with PAF induced NO production in a dose-dependent manner, although the production was lower than that induced by IFN-
.
PAF-induced NO production was shown to be inhibited by the PAF receptor
antagonist WEB 2170, and lyso-PAF, an inactive metabolite, had no
effect on NO production. Together, these two pieces of evidence suggest
that a specific interaction between PAF and its receptor on the
macrophage is responsible for the induction of NO synthesis.
The addition of a neutralizing anti-TNF-
MAb blocked the
PAF-mediated NO production. One interesting possibility raised by these
results is that PAF induces TNF-
synthesis, which, in turn, leads to
iNOS induction and NO production in infected macrophages. In addition,
the ability of WEB 2170 to inhibit the production of NO by T. cruzi-infected macrophages (Fig. 2 and data not shown) raises the
possibility that PAF plays an essential role in signal transduction
pathways necessary for NO production, possibly via induction of TNF-
(11). We are presently addressing these possibilities.
Since PAF increased NO production in infected macrophages, we
investigated whether it could induce a cytotoxic or cytostatic effect
on intracellular growth of T. cruzi. We found a direct correlation between the ability of PAF to induce NO production and its
capacity to decrease intracellular parasite replication, since
PAF-induced NO production and microbicidal activity were both inhibited
by either WEB 2170 or L-NMMA. Moreover, the addition of
lyso-PAF had no effect on intracellular parasite growth or NO
production. Interestingly, we also found that PAF potentiates macrophage trypanocidal activity when added simultaneously with low
doses of IFN-
(data not shown). These data suggest that PAF binding
and signaling through a specific receptor lead to parasite killing via
the NO pathway, in the early stages of parasite infection in vivo.
These results are in agreement with the data showing an ability of PAF
to induce NO production in different situation (27);
however, they are the first to show the importance of PAF in resistance
against T. cruzi infection in vitro.
To evaluate the role of PAF in the control of parasite replication in
vivo, we treated T. cruzi-infected mice with WEB 2170, a PAF
receptor antagonist. We found significantly higher parasitemia and
earlier mortality in WEB 2170-treated mice, demonstrating a decreased
resistance of these animals to infection with T. cruzi. Similar results were obtained with another PAF receptor antagonist, UK-74505 (data not shown). Since interleukin-12 (IL-12) is induced during T. cruzi infections (1) and this cytokine
was found to be involved in the induction of PAF synthesis by
polymorphonuclear cells and NK cells (2), it seems
reasonable to suggest that PAF is produced endogenously in T. cruzi-infected mice and, according to the results presented above,
mediates resistance to the infection by controlling parasite
replication. However, the role of T. cruzi-induced IL-12 on
PAF induction during in vivo infections remains to be elucidated.
Recently, it has been shown that Candida albicans-infected mice produced PAF, which is involved in resistance to infection via
production of TNF-
(15). Since NO is thought to be
involved in the control of C. albicans replication, it is
possible that the PAF-mediated resistance to infection with this fungus
is mediated by NO, which is the end product of an activation cascade
initiated by PAF and TNF-
. The possible interaction between
endogenously produced PAF and TNF-
in T. cruzi-infected
mice is currently being investigated in our laboratories.
The results of the present study suggest that PAF is produced during
T. cruzi infection and, together with parasite-induced proinflammatory cytokines, including TNF-
(25), IFN-
(5, 24, 26), and IL-12 (1), mediates resistance
to infection. Thus, neutralization of these proinflammatory cytokines
or blockade of the PAF receptor leads to exacerbation of parasitemia
and early death, suggesting that these molecules might be involved in
the effector responses to the parasite. Another relevant issue concerns a possible role for PAF in acute myocarditis in T. cruzi-infected mice. Since this molecule is a chemoattractant for
several leukocyte populations, it is possible that trypomastigote forms
present in the heart induce PAF secretion, which in turn leads to
inflammatory-cell infiltration and production of proinflammatory
cytokines in this tissue (6). Finally, it will be important
to define a role for PAF during infection with other protozoa, such as
Leishmania major and Toxoplasma gondii, for which
protective responses are also dependent on NO production.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from FAPESP (96/4118-9 and
97/11640-6), CNPq, and WHO/TDR (970728).
We thank Luisa K. P. Arruda, Dragana Jancovic, and George Yap for
critical reading and comments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Immunology, FMRP/USP, Ribeirão Preto
SP 14049-900, Brazil.
Phone: 55-16-602-3234. Fax: 55-16-633-6631. E-mail:
jsdsilva{at}fmrp.usp.br.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Aliberti, J. C.,
M. A. Cardoso,
G. A. Martins,
R. T. Gazzinelli,
L. Q. Vieira, and J. S. Silva.
1996.
Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes.
Infect. Immun.
64:1961-1967[Abstract].
|
| 2.
|
Bussolati, B.,
F. Mariano,
A. Cignetti,
A. Guarini,
V. Cambi,
R. Foa,
G. Piccoli, and G. Camussi.
1998.
Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis.
J. Immunol.
161:1493-1500[Abstract/Free Full Text].
|
| 3.
|
Braquet, P.,
L. Touqui,
T. Y. Shen, and B. B. Vargaftig.
1987.
Perspectives in platelet-activating factor research.
Pharmacol. Rev.
39:97-145[Medline].
|
| 4.
|
Camussi, G.,
M. Aglietta,
R. Coda,
F. Bussolino,
W. Piacibello, and C. Tetta.
1981.
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils.
Immunology
42:191-199[Medline].
|
| 5.
|
Cardillo, F.,
J. C. Voltarelli,
S. G. Reed, and J. S. Silva.
1996.
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells.
Infect. Immun.
64:128-134[Abstract].
|
| 6.
|
Chandrasekar, B.,
P. C. Melby,
D. A. Troyer,
J. T. Colston, and G. L. Freeman.
1998.
Temporal expression of pro-inflammatory cytokines and inducible nitric oxide synthase in experimental acute Chagasic cardiomyopathy.
Am. J. Pathol.
152:925-934[Abstract].
|
| 7.
|
Chao, W., and M. S. Olson.
1993.
Platelet-activating factor: receptors and signal transduction.
Biochem. J.
292:617-629.
|
| 8.
|
Chignardi, M.,
J. P. Le Couedic,
M. Tence,
B. B. Vargaftig, and J. Benveniste.
1979.
The role of platelet-activating factor in platelet aggregation.
Nature
279:799-800[Medline].
|
| 9.
|
Ding, A.,
C. F. Nathan, and D. J. Stuher.
1988.
Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production.
J. Immunol.
141:2407-2412[Abstract].
|
| 10.
|
Drapier, J. C.,
J. Wietzerbin, and J. B. Hibbs, Jr.
1988.
Interferon-gamma and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages.
Eur. J. Immunol.
18:1587-1592[Medline].
|
| 11.
|
Dubois, C.,
E. Bissonnette, and M. Rola-Pleszczynski.
1989.
Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors.
J. Immunol.
143:964-970[Abstract].
|
| 12.
|
Gazzinelli, R. T.,
I. P. Oswald,
S. Hienry,
S. L. James, and A. Sher.
1992.
The microbicidal activity of interferon- -treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor- .
Eur. J. Immunol.
22:2501-2506[Medline].
|
| 13.
|
Howard, A. D., and K. L. Erickson.
1995.
The induction and augmentation of macrophage tumoricidal responses by platelet-activating factor.
Cell. Immunol.
164:105-112[Medline].
|
| 14.
|
Im, S.-Y.,
H.-M. Ko,
Y.-S. Ko,
J.-W. Kim,
H.-K. Lee,
T.-Y. Ha,
H. B. Lee,
S.-J. Oh,
S. Bai,
K.-C. Chung,
Y.-B. Lee,
H.-S. Kang, and S.-B. Chun.
1996.
Augmentation of tumor metastasis by platelet-activating factor.
Cancer Res.
56:2662-2665[Abstract/Free Full Text].
|
| 15.
|
Im, S.-Y.,
J.-H. Choi,
H.-M. Ko,
S.-J. Han,
S.-B. Chun,
H.-K. Lee, and T.-Y. Ha.
1997.
A protective role of platelet-activating factor in murine candidiasis.
Infect. Immun.
65:1321-1326[Abstract].
|
| 16.
|
Ishii, S.,
T. Kuwaki,
T. Nagase,
K. Maki,
F. Tashiro,
S. Sunaga,
W.-H. Cao,
K. Kume,
Y. Fukuchi,
K. Ikuta,
J.-I. Miyazaki,
M. Kumada, and T. Shimizu.
1998.
Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor.
J. Exp. Med.
187:1779-1788[Abstract/Free Full Text].
|
| 17.
|
Melo, R. C., and Z. Brener.
1978.
Tissue tropism of different Trypanosoma cruzi strains.
J. Parasitol.
64:475-482[Medline].
|
| 18.
|
Mencia-Huerta, J. M., and J. Benveniste.
1979.
Platelet-activating factor and macrophage. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes.
Eur. J. Immunol.
9:409-415[Medline].
|
| 19.
|
Moncada, S., and A. Higgs.
1993.
The L-arginine-nitric oxide pathway.
N. Engl. J. Med.
30:2002-2012.
|
| 20.
|
Nathan, C., and Q.-W. Xie.
1994.
Nitric oxide synthases: roles, tools and controls.
Cell
78:915-918[Medline].
|
| 21.
|
Nathan, C.
1993.
Nitric oxide as a secretory product of mammalian cells.
FASEB J.
6:3051-3064[Abstract].
|
| 22.
|
Negro-Alvarez, J. M.,
J. C. M. Lopez,
J. L. O. Martinez,
A. A. Aleman, and R. Rubio del Barrio.
1997.
Platelet-activating factor antagonists.
Allergol. Immunopathol.
25:249-258[Medline].
|
| 23.
|
Petray, P.,
M. E. Rottenberg,
S. Grinstein, and A. Orn.
1994.
Release of nitric oxide during the experimental infection with Trypanosoma cruzi.
Parasite Immunol.
16:193-199[Medline].
|
| 24.
|
Plata, F.,
J. Wietzerbin,
F. G. Ons,
E. Falcoff, and H. Eisen.
1984.
Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro.
Eur. J. Immunol.
14:930-935[Medline].
|
| 25.
|
Silva, J. S.,
G. N. R. Vespa,
M. A. G. Cardoso,
J. C. S. Aliberti, and F. Q. Cunha.
1995.
Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.
Infect. Immun.
63:4862-4867[Abstract].
|
| 26.
|
Silva, J. S.,
P. J. Morrissey,
K. H. Grabstein,
K. M. Mohler,
D. Anderson, and S. G. Reed.
1992.
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection.
J. Exp. Med.
175:169-174[Abstract/Free Full Text].
|
| 27.
|
Steil, A. A.,
M. C. Garcia Rodriguez,
A. Alonso,
M. S. Crespo, and L. Bosca.
1995.
Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis.
Br. J. Pharmacol.
114:895-901[Medline].
|
| 28.
|
Szabo, C.,
C. C. Wu,
J. A. Mitchell,
S. S. Gross,
C. Thiemermann, and J. R. Vane.
1993.
Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipolysaccharide.
Circ. Res.
73:991-999[Abstract/Free Full Text].
|
| 29.
|
Vespa, G. N. R.,
F. Q. Cunha, and J. S. Silva.
1994.
Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro.
Infect. Immun.
62:5177-5182[Abstract/Free Full Text].
|
Infection and Immunity, June 1999, p. 2810-2814, Vol. 67, No. 6
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
van Zoelen, M. A. D., Florquin, S., Meijers, J. C. M., de Beer, R., de Vos, A. F., de Boer, O. J., van der Poll, T.
(2008). Platelet-Activating Factor Receptor Contributes to Host Defense against Pseudomonas aeruginosa Pneumonia but Is Not Essential for the Accompanying Inflammatory and Procoagulant Response. J. Immunol.
180: 3357-3365
[Abstract]
[Full Text]
-
Lattin, J., Zidar, D. A., Schroder, K., Kellie, S., Hume, D. A., Sweet, M. J.
(2007). G-protein-coupled receptor expression, function, and signaling in macrophages. J. Leukoc. Biol.
82: 16-32
[Abstract]
[Full Text]
-
Talvani, A., Machado, F. S., Santana, G. C., Klein, A., Barcelos, L., Silva, J. S., Teixeira, M. M.
(2002). Leukotriene B4 Induces Nitric Oxide Synthesis in Trypanosoma cruzi-Infected Murine Macrophages and Mediates Resistance to Infection. Infect. Immun.
70: 4247-4253
[Abstract]
[Full Text]
-
Lonardoni, M. V. C., Russo, M., Jancar, S.
(2000). Essential Role of Platelet-Activating Factor in Control of Leishmania (Leishmania) amazonensis Infection. Infect. Immun.
68: 6355-6361
[Abstract]
[Full Text]